A venture capital firm is part of a large investment holding company with over €25 billion in assets under management. The firm actively seeks early-stage investment opportunities in global companies that offer disruptive therapeutic approaches across modalities and disease areas, specifically addressing unmet medical needs. The firm offers evergreen support until key value-added milestones and meaningful impact are achieved. Investment sizes typically range from 1 to 10 million euros, with the capacity for larger follow-on investments in portfolio companies. The firm is open to participation at any stage, with a preference for Seed to Series B rounds. The firm’s willingness to lead or co-invest extends to companies in Spain and Portugal, and the firm also participates as a co-investor globally, with a special focus on the EU.
The firm is a flexible and opportunistic investor that is currently considering disruptive therapeutics companies in areas of unmet need. The firm will look at opportunities of all stages from pre-clinical to phase I/II.
The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment